Sunday, November 29 | 10:30 a.m.-11:30 a.m. | S2-SSNMMI01-6 | Room S405
Gallium-68 (Ga-68) arginine-glycine-aspartate (RGD) PET/CT offers complementary staging value to F-18 FDG-PET/CT in breast cancer, suggest findings from a small pilot study in this session.
In a study of 30 consecutive patients with histologically confirmed breast cancer, presenter Juan Molina, MD, of Children’s Hospital Los Angeles, and colleagues compared Ga-68 RGD and FDG-PET/CT on primary tumor uptake, tumor-to-background ratio (TBR), and axillary nodal concordance across luminal, HER2-enriched, and triple-negative subtypes.
Median primary lesion maximum standard uptake value (SUVmax) was similar between tracers: 8.50 for Ga-68 RGD versus 6.55 for FDG-PET, with no statistically significant difference. Tumor background ratio (TBR) favored Ga-68 RGD: 8.50 versus 2.62. Axillary nodal staging showed substantial agreement between the two tracers (Cohen kappa = 0.783), with Ga-68 RGD detecting nodal disease in 18 patients compared with 21 for FDG-PET.
Integrin αvβ3 overexpression drives tumor angiogenesis in breast cancer and is targetable by RGD peptides, making Ga-68 RGD a candidate to complement FDG-PET, particularly where FDG uptake is suboptimal, the authors noted.
“Superior TBR and discordant primary-lesion uptake suggest added value in subsets with suboptimal FDG performance. Molecular-subtype stratified prospective validation is warranted,” the authors wrote.
Grab a coffee and catch this Monday morning session to learn more.



